So lutetium PSMA is an exciting treatment for prostate cancer and it’s been adopted as a standard again in many countries. As new and exciting treatments are being developed, if they’re going to be used following lutetium PSMA, we need to understand what the outcomes are for patients who have received a lutetium PSMA. So we collaborated with Flatiron to look at real-world evidence to see what the survival would be like for people who have been treated with a lutetium PSMA...
So lutetium PSMA is an exciting treatment for prostate cancer and it’s been adopted as a standard again in many countries. As new and exciting treatments are being developed, if they’re going to be used following lutetium PSMA, we need to understand what the outcomes are for patients who have received a lutetium PSMA. So we collaborated with Flatiron to look at real-world evidence to see what the survival would be like for people who have been treated with a lutetium PSMA. So we collaborated with Flatiron to look at real-world evidence to see what the survival would be like for people who have been treated with a lutetium PSMA, and we found that the outcomes are quite poor. The median survival was around eight months. If you’d had chemotherapy before lutetium PSMA, your outcome’s even poorer, around a median of about six months. If you hadn’t had chemotherapy yet, then most patients were challenged with chemotherapy following lutetium, and their outcomes were slightly better, around the median overall survival of about 14 months. So these data are really important to understand that there is a strong area of need to develop treatments following lutetium PSMA, and it gives a good sense about how well that control line might perform for clinical trials in that space.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
